HeartSciences’ MyoVista Insights™ Receives Epic Toolbox Designation for ECG Management System Category

Rhea-AI Summary

HeartSciences (Nasdaq: HSCS) announced that its MyoVista Insights platform received Epic Toolbox designation for the ECG Management System category on March 25, 2026. The cloud-native platform supports HL7v2 order/results, SSO, and SMART on FHIR to integrate with Epic EHR workflows.

This designation signals that MyoVista Insights meets Epic’s recommended practices for ECG integrations and is listed on Epic Showroom, enabling clinicians to access the platform within existing EHR workflows.

News Market Reaction – HSCS

+1.68%

+1.68% Session close to close

In the Mar 25 session, HSCS gained 1.68%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights an interoperability milestone, with MyoVista Insights meeting Epic Tool...

Analysis

This announcement highlights an interoperability milestone, with MyoVista Insights meeting Epic Toolbox practices for the ECG Management System category and supporting HL7v2, SSO, and SMART on FHIR workflows. In recent months, HeartSciences has combined similar commercial and integration advances with loss-making financials and no meaningful revenue. Investors should monitor how Epic-enabled access translates into concrete deployments, revenue growth, and progress on previously disclosed going-concern and capital-raising needs.

Key Figures

Epic listing ID: 3509 Announcement date: March 25, 2026

2 metrics

Epic listing ID 3509 MyoVista Insights entry on Epic Showroom Toolbox

Announcement date March 25, 2026 News release date for Epic Toolbox designation

Historical Context

5 past events · Latest: Mar 24 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 24	Investor conference	Neutral	-1.6%	Announcement of virtual investor conference presentation and one-on-one meetings.
Mar 16	Earnings update	Negative	-0.4%	FQ3 2026 results with no meaningful revenue and limited cash resources.
Feb 05	Platform adoption	Positive	-3.8%	UWE adopts MyoVista Insights and wavECG for an ECG education center.
Jan 29	Network endorsement	Positive	+2.1%	Cibolo Health endorses MyoVista Insights for 123 independent hospitals.
Dec 15	Earnings update	Negative	-6.5%	FQ2 2026 loss-making quarter with no meaningful revenue and going-concern risk.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news often met with modest price changes, including negative reactions to both positive adoption wins and loss-making earnings updates.

Recent Company History

Over the last few months, HeartSciences has reported no meaningful revenue in both FQ2 and FQ3 2026 while advancing its MyoVista Insights platform and pursuing FDA 510(k) clearance for the MyoVista wavECG device. Operationally, it secured an endorsement across 123 hospitals via Cibolo Health and an adoption at the University of the West of England. Despite these wins, several prior announcements, including earnings and commercial updates, were followed by negative price reactions. Today’s Epic Toolbox designation fits into this commercialization and integration narrative.

Key Terms

electrocardiography, ecg, ekg, artificial intelligence, +4 more

8 terms

electrocardiography medical

"focused on advancing electrocardiography (“ECG” or “EKG”) through the integration"

Electrocardiography is a medical test that records the heart’s electrical signals using sensors on the skin, producing a tracing that shows heart rhythm and timing. Investors should care because these readings are routinely used to assess the safety and effectiveness of drugs, medical devices, and treatments—like checking a building’s wiring for faults—so abnormal results can affect clinical trial outcomes, regulatory approval, and product marketability.

ecg medical

"advancing electrocardiography (“ECG” or “EKG”) through the integration of"

An ECG (electrocardiogram) records the heart’s electrical activity through small sensors on the skin and produces a waveform that shows heart rate, rhythm and signs of stress or damage—think of it as a seismograph for the heart’s electrical signals. Investors care because ECGs are central to diagnosing and monitoring cardiac safety in clinical trials, required for regulatory approval of many drugs and devices, and drive demand for related medical equipment and services.

ekg medical

"electrocardiography (“ECG” or “EKG”) through the integration of artificial"

An EKG is a short test that records the heart’s electrical activity using sensors on the skin, producing a simple tracing like a road map of each heartbeat. Investors care because EKG results are used to spot heart-related side effects or safety signals in drug trials and medical devices, and clear or abnormal EKG findings can affect regulatory approval, trial continuation, product liability, and market value.

artificial intelligence technical

"through the integration of artificial intelligence (“AI”), today announced that"

Artificial intelligence is the ability of computers and machines to perform tasks that typically require human thinking, such as understanding language, recognizing patterns, or making decisions. For investors, it matters because AI can enhance efficiency, uncover new insights, and enable smarter strategies, potentially impacting the value and performance of companies that develop or utilize this technology.

ehrs technical

"systems and electronic health records (“EHRs”), including Epic, through HL7v2"

Electronic health records (EHRs) are digital versions of patients’ medical charts that store diagnoses, test results, prescriptions and treatment histories in a searchable, shareable format—think of them as a secure, cloud-accessible filing cabinet for a person’s health information. Investors care because widespread EHR use shapes healthcare costs, compliance, and service efficiency; EHR vendors, hospitals and health-tech firms can see revenue and risk tied to adoption rates, data security, and how easily systems exchange information.

hl7v2 technical

"including Epic, through HL7v2 order and results workflows, single sign-on"

HL7v2 is a widely used technical standard that defines how healthcare software systems format and exchange clinical and administrative messages—such as lab results, patient admissions, and medication orders—so different systems can understand each other. For investors, HL7v2 matters because support or compatibility affects a health-technology product’s ability to connect with hospitals and clinics, influencing sales, implementation costs, customer adoption, and regulatory integration risks.

single sign-on technical

"Epic, through HL7v2 order and results workflows, single sign-on (“SSO”), and"

Single sign-on is a technology that lets a person log in once and then access multiple applications or systems without re-entering credentials, like using one key that opens every door in a building. For investors, it matters because it can reduce IT support costs, speed employee workflows and improve user experience, while also concentrating cybersecurity risk and affecting compliance posture—factors that influence operational efficiency and potential liability.

smart on fhir technical

"workflows, single sign-on (“SSO”), and SMART on FHIR. These capabilities enable"

A technical standard that lets third‑party apps securely plug into electronic health records and other clinical systems the way apps plug into a smartphone. It defines a common way to request and share medical data and to manage user permissions, so developers can build interoperable tools once and run them across many healthcare systems. For investors, it matters because wider adoption lowers integration costs, expands addressable markets, and speeds product rollouts in health IT.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Southlake, TX , March 25, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc.  (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), today announced that its MyoVista Insights™ platform has received Epic Toolbox designation for the ECG Management System category.

MyoVista Insights is a cloud-native ECG management and analysis platform designed to enhance workflow efficiency and support clinical decision-making. The platform supports integration with hospital information systems and electronic health records (“EHRs”), including Epic, through HL7v2 order and results workflows, single sign-on (“SSO”), and SMART on FHIR. These capabilities enable clinicians to access MyoVista Insights™ within their existing clinical workflows.

MyoVista Insights is in Epic Toolbox and meets Epic’s recommended practices for integrations in the ECG Management System category. You can find MyoVista Insights in Toolbox on Epic Showroom at: https://showroom.epic.com/Listing?id=3509

Andrew Simpson, Chief Executive Officer of HeartSciences, said, “Receiving Epic Toolbox designation is an important milestone in our interoperability strategy. We are focused on enabling seamless integration of MyoVista Insights™ into clinical workflows and expanding access to our platform across healthcare systems.”

For more information about MyoVista Insights™, please visit www.heartsciences.com or follow the Company on X (@HeartSciences). Healthcare providers interested in opportunities may contact info@heartsciences.com.

Epic is a registered trademark of Epic Systems Corporation.

About HeartSciences

HeartSciences is a healthcare information technology (“HIT”) company advancing the use of ECG/EKGs through the integration of artificial intelligence (“AI”). The Company’s MyoVista Insights platform is a device-agnostic, next-generation ECG management system designed to improve clinical efficiency and decision-making. Its MyoVista wavECG device is designed to deliver conventional ECG functionality while supporting on-device AI-enabled solutions

For more information, please visit: https://www.heartsciences.com. X: @HeartSciences

Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are made under the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Company's future financial and operating performance. All statements, other than statements of historical facts, included herein are "forward-looking statements" including, among other things, statements about HeartSciences' beliefs and expectations. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. The expectations reflected in these forward-looking statements involve significant assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Potential risks and uncertainties include, but are not limited to, risks discussed in HeartSciences' Annual Report on Form 10-K for the fiscal year ended April 30, 2025, filed with the U.S. Securities and Exchange Commission (the "SEC") on July 24, 2025, HeartSciences’ Quarterly Report on Form 10-Q for the fiscal quarter ended July 31, 2025 filed with the SEC on September 11, 2025, HeartSciences’ Quarterly Report on Form 10-Q for the fiscal quarter ended October 31, 2025 filed with the SEC on December 15, 2025, HeartSciences’ Quarterly Report on Form 10-Q for the fiscal quarter ended January 31, 2026 filed with the SEC on March 16, 2026, and in HeartSciences' other filings with the SEC at www.sec.gov. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

Investor Relations:
Integrous Communications
Mark Komonoski, Partner
Phone: 877 255 8483
Email: mkomonoski@integcom.us

Media Contact:
HeartSciences
Gene Gephart
Phone: +1 682 244 2578 Ext. 2024
Email: info@heartsciences.com

FAQ

What does Epic Toolbox designation mean for HeartSciences (HSCS) and MyoVista Insights on March 25, 2026?

It means MyoVista Insights meets Epic’s recommended integration practices for ECG systems. According to HeartSciences, the designation confirms compatibility with Epic workflows and visibility on Epic Showroom, which may simplify hospital adoption and clinical access to the platform.

How does MyoVista Insights integrate with Epic EHR systems for hospitals evaluating HSCS solutions?

MyoVista Insights integrates using HL7v2 order/results, single sign-on, and SMART on FHIR. According to HeartSciences, these interfaces let clinicians access ECG data and analysis inside Epic workflows without separate logins or custom interfaces.

Where can clinicians or IT teams find MyoVista Insights listed in Epic resources for HSCS evaluation?

MyoVista Insights is listed in Epic Toolbox on Epic Showroom (listing ID 3509). According to HeartSciences, the listing provides technical and integration details to help health systems assess compatibility and deployment requirements.

Will the Epic Toolbox designation allow MyoVista Insights to appear inside clinicians’ Epic workflows?

Yes — the designation indicates the platform supports embedded access patterns within Epic. According to HeartSciences, MyoVista Insights’ SSO and SMART on FHIR capabilities enable clinicians to open the platform inside Epic clinical workflows.

Who should healthcare providers contact at HeartSciences for integration or partnership inquiries about MyoVista Insights?

Providers can contact the company via info@heartsciences.com for opportunities and integration discussions. According to HeartSciences, the team can provide technical details, implementation guidance, and next steps for evaluating MyoVista Insights with Epic.